Product Description
PF-2545920 is an orally-active phosphodiesterase 10A (PDE10A) inhibitor originated by Pfizer, for the treatment of Huntington's disease.ÊPF-2545920 is active in a range of antipsychotic models, antagonizing apomorphine-induced climbing in mice, inhibiting conditioned avoidance responding in both rats and mice, and blocking N-methyl-D-aspartate antagonist-induced deficits in prepulse inhibition of acoustic startle response in rats, while improving baseline sensory gating in mice. (Sourced from: https://drugs.ncats.io/drug/R9Y8EY0G42)
Mechanisms of Action: DprE1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Huntington Disease|Schizophrenia
Phase 1: Healthy Volunteers|Psychotic Disorders|Schizophrenia|Affective Disorders, Psychotic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01918202 |
PET | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |
2019-03-19 |
Treatments |
|
NCT01829048 |
A8241018 | P1 |
Completed |
Schizophrenia |
2013-10-17 |
2019-03-19 |
Treatments |
|
NCT01244880 |
A8241014 | P1 |
Terminated |
Healthy Volunteers |
2012-08-01 |
2019-03-19 |
Treatments |
|
NCT01103726 |
A8241013 | P1 |
Completed |
Healthy Volunteers |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT00463372 |
A8241002 | P1 |
Completed |
Psychotic Disorders|Affective Disorders, Psychotic|Schizophrenia |
None |
2019-03-21 |
Treatments |
|
NCT02342548 |
A8241022 | P2 |
Terminated |
Huntington Disease |
2017-02-06 |
2019-03-20 |
||
2014-004900-31 |
2014-004900-31 | P2 |
Terminated |
Huntington Disease |
2017-02-06 |
2022-03-13 |
Treatments |
|
2014-001291-56 |
2014-001291-56 | P2 |
Completed |
Huntington Disease |
2016-10-04 |
2022-03-13 |
||
NCT02197130 |
A8241021 | P2 |
Completed |
Huntington Disease |
2016-09-01 |
2019-03-20 |
||
NCT01806896 |
A8241016 | P2 |
Completed |
Huntington Disease |
2015-01-01 |
2019-03-19 |
Treatments |
|
NCT01939548 |
A8241019 | P2 |
Terminated |
Schizophrenia |
2014-10-01 |
2019-03-20 |
Treatments |
|
2010-020764-38 |
2010-020764-38 | P2 |
Completed |
Schizophrenia |
2011-08-04 |
2022-03-13 |
||
NCT01175135 |
A8241012 | P2 |
Completed |
Schizophrenia |
2011-08-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT00570063 |
A8241006 | P2 |
Terminated |
Schizophrenia |
2008-02-18 |
2019-03-22 |
Treatments |